Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
STALICLA Starts Phase 3 DDI Study of STP7 to Treat Cocaine Use Disorder in the U.S.
Details : STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5...
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement